Nolte F - Search Results

1

Depolarisation of the plasma membrane in the arsenic trioxide (As2O3)-and anti-CD95-induced apoptosis in myeloid cells.

Nolte F, Friedrich O, Rojewski M, Fink RH, Schrezenmeier H, Körper S. Nolte F, et al. FEBS Lett. 2004 Dec 3;578(1-2):85-9. doi: 10.1016/j.febslet.2004.10.075. FEBS Lett. 2004. PMID: 15581621 Free article.

2

The K+ channel openers diazoxide and NS1619 induce depolarization of mitochondria and have differential effects on cell Ca2+ in CD34+ cell line KG-1a.

Körper S, Nolte F, Rojewski MT, Thiel E, Schrezenmeier H. Körper S, et al. Among authors: nolte f. Exp Hematol. 2003 Sep;31(9):815-23. doi: 10.1016/s0301-472x(03)00199-1. Exp Hematol. 2003. PMID: 12962728 Free article.

3

The role of mitochondrial targeting in arsenic trioxide-induced apoptosis in myeloid cell lines.

Körper S, Nolte F, Thiel E, Schrezenmeier H, Rojewski MT. Körper S, et al. Among authors: nolte f. Br J Haematol. 2004 Jan;124(2):186-9. doi: 10.1046/j.1365-2141.2003.04742.x. Br J Haematol. 2004. PMID: 14687028 Free article.

4

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H. Nolte F, et al. Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17. Ann Hematol. 2013. PMID: 23073603 Clinical Trial.

5

Myelodysplastic syndromes: molecular pathogenesis and genomic changes.

Nolte F, Hofmann WK. Nolte F, et al. Ann Hematol. 2008 Oct;87(10):777-95. doi: 10.1007/s00277-008-0502-z. Epub 2008 May 31. Ann Hematol. 2008. PMID: 18516602 Review.

6

Genome-wide DNA-mapping of CD34+ cells from patients with myelodysplastic syndrome using 500K SNP arrays identifies significant regions of deletion and uniparental disomy.

Nowak D, Nolte F, Mossner M, Nowak V, Baldus CD, Hopfer O, Noll S, Thiel E, Wagner F, Hofmann WK. Nowak D, et al. Among authors: nolte f. Exp Hematol. 2009 Feb;37(2):215-224. doi: 10.1016/j.exphem.2008.10.012. Exp Hematol. 2009. PMID: 19135900 Free article.

7

Molecular mechanisms involved in the progression of myelodysplastic syndrome.

Nolte F, Hofmann WK. Nolte F, et al. Future Oncol. 2010 Mar;6(3):445-55. doi: 10.2217/fon.09.175. Future Oncol. 2010. PMID: 20222800 Review.

8

[Current treatment options for myelodysplastic syndromes].

Nolte F, Hofmann WK. Nolte F, et al. Dtsch Med Wochenschr. 2010 Sep;135(38):1863-9. doi: 10.1055/s-0030-1263328. Epub 2010 Sep 14. Dtsch Med Wochenschr. 2010. PMID: 20842606 Review. German. No abstract available.

9

Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox.

Nolte F, Angelucci E, Beris P, Macwhannell A, Selleslag D, Schumann C, Xicoy B, Almeida A, Guerci-Bresler A, Sliwa T, Muus P, Porter J, Hofmann WK. Nolte F, et al. Leuk Res. 2011 Sep;35(9):1131-5. doi: 10.1016/j.leukres.2011.06.013. Epub 2011 Jul 6. Leuk Res. 2011. PMID: 21737138

10

Characteristics of MDS patients seen at private practices differ significantly from those treated at university hospitals in Germany.

Nolte F, Schumann C, Klein S, Reinwald M, Hofmann WK. Nolte F, et al. J Cancer Res Clin Oncol. 2012 Jun;138(6):953-7. doi: 10.1007/s00432-012-1168-4. Epub 2012 Feb 23. J Cancer Res Clin Oncol. 2012. PMID: 22358300

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

233 results

Search Page

Filters